Can a lower dose keep leukemia in check?
Disease control
ENROLLING_BY_INVITATION
This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia (CML) in patients whose cancer has already responded well to treatment. About 100 adults with CML in chronic or accelerated phase will take a lower dose (20 mg ever…
Sponsor: Qian Jiang • Aim: Disease control
Last updated May 26, 2026 10:41 UTC